Latest News

Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer


CASTRES, France–(BUSINESS WIRE)–Pierre Fabre today announced interim analysis results from the Phase 3 BEACON CRC trial evaluating the combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor, and ERBITUX® (cetuximab), an anti-EGFR antibody (encorafenib Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. Results showed that patients with BRAF-mutant mCRC treated with the encorafenib Triplet combinat

Source link




Related posts

Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Newsemia

Chemotherapy can cause drug-resistant mutations in pediatric ALL patients who relapse

Newsemia

Exercise Significantly Reduces Depression, Study Says

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy